Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review.
Acitretin
Alitretinoin
Hidradenitis suppurativa
Isotretinoin
Retinoids
Topical retinoids
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
08
01
2024
accepted:
15
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
Hidradenitis suppurativa (HS) is a debilitating chronic skin disorder characterized by painful inflammatory nodules, abscesses and sinus tracts involving intertriginous areas and has an adverse impact on patient quality of life. Over the past decade, the therapeutic options of HS have increased significantly to comprise multiple modalities, including topical medication, systemic therapies (mainly antibiotics, retinoids, and biologics), surgical approaches, and lifestyle modifications. Biologics alone or in combination with surgery remain the treatment of choice for moderate to severe disease. However, non-biologic therapies (including retinoids) may be used as monotherapy for mild disease and in combination with biologics and surgical treatment in moderate to severe disease. Retinoids, specifically isotretinoin, acitretin, and alitretinoin, are historically used in the management of HS, supported by anecdotal evidence and with variable treatment response. Although the current American and European guidelines offer different recommendations on the use of retinoids in HS, retinoids remain a valuable ally in HS management. This review provides a comprehensive analysis of the current scientific literature on retinoid therapy (topical and systemic) in HS, highlighting disparities in mechanisms of action, efficacy, and safety to clarify their role in HS treatment.
Identifiants
pubmed: 38700645
doi: 10.1007/s13555-024-01169-1
pii: 10.1007/s13555-024-01169-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Molinelli E, Gioacchini H, Sapigni C, Diotallevi F, Brisigotti V, Rizzetto G, et al. New insight into the molecular pathomechanism and immunomodulatory treatments of hidradenitis suppurativa. Int J Mol Sci. 2023;24:8428.
pubmed: 37176138
pmcid: 10179439
doi: 10.3390/ijms24098428
Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18:6131.
pubmed: 34204126
pmcid: 8201351
doi: 10.3390/ijerph18116131
Bianchi L, Caposiena Caro RD, Ganzetti G, Molinelli E, Dini V, Oranges T, et al. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort. Clin Exp Dermatol. 2019;44:e177–80.
pubmed: 30593710
doi: 10.1111/ced.13861
Napolitano M, Megna M, Timoshchuk E, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105–15.
pubmed: 28458570
pmcid: 5402905
doi: 10.2147/CCID.S111019
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73:S8-11.
pubmed: 26470623
doi: 10.1016/j.jaad.2015.07.045
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44.
pubmed: 25640693
doi: 10.1111/jdv.12966
Kathju S, Lasko L-A, Stoodley P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol. 2012;65:385–9.
pubmed: 22353357
doi: 10.1111/j.1574-695X.2012.00946.x
Bechara FG, Sand M, Skrygan M, Kreuter A, Altmeyer P, Gambichler T. Acne inversa: evaluating antimicrobial peptides and proteins. Ann Dermatol. 2012;24:393.
pubmed: 23197903
pmcid: 3505768
doi: 10.5021/ad.2012.24.4.393
Zouboulis CC, del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–90.
pubmed: 26139027
doi: 10.1159/000431175
Napolitano M, Calzavara-Pinton PG, Zanca A, Bianchi L, Caposiena Caro RD, Offidani AM, et al. Comparison of clinical and ultrasound scores in patients with hidradenitis suppurativa: results from an Italian ultrasound working group. J Eur Acad Dermatol Venereol. 2019. https://doi.org/10.1111/jdv.15235 .
doi: 10.1111/jdv.15235
pubmed: 31535763
Lacarrubba F, Dini V, Napolitano M, Venturini M, Caposiena Caro DR, Molinelli E, et al. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience. J Eur Acad Dermatol Venereol. 2019;33:10–4.
pubmed: 31535763
doi: 10.1111/jdv.15847
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81:91–101.
pubmed: 30872149
pmcid: 9131892
doi: 10.1016/j.jaad.2019.02.068
Molinelli E, Brisigotti V, Simonetti O, Sapigni C, D’Agostino GM, Rizzetto G, et al. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: a retrospective study. Dermatol Ther. 2022. https://doi.org/10.1111/dth.15439 .
doi: 10.1111/dth.15439
pubmed: 35903895
pmcid: 9539466
Molinelli E, Brisigotti V, Simonetti O, Campanati A, Sapigni C, D’Agostino GM, et al. Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol. 2020;183:1117–9.
pubmed: 32579711
doi: 10.1111/bjd.19337
Saunte DML, Jemec GBE. Hidradenitis suppurativa. JAMA. 2017;318:2019.
pubmed: 29183082
doi: 10.1001/jama.2017.16691
Molinelli E, De Simoni E, Candelora M, Sapigni C, Brisigotti V, Rizzetto G, et al. Systemic antibiotic therapy in hidradenitis suppurativa: a review on treatment landscape and current issues. Antibiotics. 2023;12:978.
pubmed: 37370297
pmcid: 10295086
doi: 10.3390/antibiotics12060978
Molinelli E, Sapigni C, D’Agostino GM, Brisigotti V, Rizzetto G, Bobyr I, et al. The effect of dalbavancin in moderate to severe hidradenitis suppurativa. Antibiotics. 2022;11:1573.
pubmed: 36358228
pmcid: 9686733
doi: 10.3390/antibiotics11111573
Molinelli E, Brisigotti V, Campanati A, Sapigni C, Giacchetti A, Cota C, et al. Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: a controlled retrospective clinical study. J Am Acad Dermatol. 2020;83:665–7.
pubmed: 32339699
doi: 10.1016/j.jaad.2020.04.092
Molinelli E, Paolinelli M, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019;15:367–79.
pubmed: 30943794
doi: 10.1080/17425255.2019.1600670
Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A. Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: a controlled prospective clinical study. J Am Acad Dermatol. 2022;87:674–5.
pubmed: 34774922
doi: 10.1016/j.jaad.2021.10.060
Molinelli E, Campanati A, Ganzetti G, Offidani A. Biologic therapy in immune mediated inflammatory disease: basic science and clinical concepts. Curr Drug Saf. 2016;11:35–43.
pubmed: 26463248
doi: 10.2174/1574886310666151014115127
Simonetti O, Lucarini G, Campanati A, Goteri G, Zizzi A, Marconi B, et al. VEGF, survivin and NOS overexpression in psoriatic skin: critical role of nitric oxide synthases. J Dermatol Sci. 2009;54:205–8.
pubmed: 19188045
doi: 10.1016/j.jdermsci.2008.12.012
Simonetti O, Ferretti G, Salvi A, Offidani AM, Bossi G. Plasma lipid changes in psoriatic children. Dermatology. 1992;185:96–100.
pubmed: 1421638
doi: 10.1159/000247421
Snyder CL, Gibson RS, Porter ML, Kimball AB. Secukinumab in the treatment of hidradenitis suppurativa. Immunotherapy. 2023;15:1449–57.
pubmed: 37840286
doi: 10.2217/imt-2023-0103
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. J Am Acad Dermatol. 2020;82:1061–82.
pubmed: 31604100
doi: 10.1016/j.jaad.2019.08.089
Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol. 2020;16:1019–37.
pubmed: 32896186
doi: 10.1080/17425255.2020.1810233
Wollina U, Brzezinski P, Koch A, Philipp-Dormston WG. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa—a narrative review. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13877 .
doi: 10.1111/dth.13877
pubmed: 33103332
pmcid: 7461387
Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004;328:1–16.
pubmed: 15019979
doi: 10.1016/j.gene.2003.12.005
Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatol Treat. 2017;28:684–96.
doi: 10.1080/09546634.2017.1309349
Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327–48.
pubmed: 18046911
pmcid: 2699641
doi: 10.2147/ciia.2006.1.4.327
Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237:81–96.
pubmed: 31645040
doi: 10.1159/000503605
Pile HD, Sadiq NM. Isotretinoin. In: StatPearls. Treasure Island: StatPearls Publishing; 2023.
Wiegand U-W, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol. 1998;39:S8-12.
pubmed: 9703117
doi: 10.1016/S0190-9622(98)70438-4
Melnik B. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Dermatol Venereol. 2017;97:173–81.
doi: 10.2340/00015555-2535
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10:2094.
pubmed: 34440863
pmcid: 8392140
doi: 10.3390/cells10082094
Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence. JAAD Int. 2020;1:62–72.
pubmed: 34409324
pmcid: 8361883
doi: 10.1016/j.jdin.2020.05.005
Bergler-Czop B, Brzezińska-Wcisło L. Pro-inflammatory cytokines in patients with various kinds of acne treated with isotretinoin. Adv Dermatol Allergol. 2014;1:21–8.
doi: 10.5114/pdia.2014.40655
Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Investig Dermatol. 2012;132:2198–205.
pubmed: 22513780
doi: 10.1038/jid.2012.111
Hessam S, Gambichler T, Höxtermann S, Skrygan M, Sand M, Garcovich S, et al. Frequency of circulating subpopulations of T-regulatory cells in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34:834–8.
pubmed: 31721309
doi: 10.1111/jdv.16071
Nolan ZT, Banerjee K, Cong Z, Gettle SL, Longenecker AL, Kawasawa YI, et al. Treatment response to isotretinoin correlates with specific shifts in Cutibacterium acnes strain composition within the follicular microbiome. Exp Dermatol. 2023;32:955–64.
pubmed: 36999947
doi: 10.1111/exd.14798
Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. 2017;153:897.
pubmed: 28538949
pmcid: 5710430
doi: 10.1001/jamadermatol.2017.0904
Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol. 2011;164:1017–22.
pubmed: 21250966
doi: 10.1111/j.1365-2133.2011.10224.x
Poli F, Revuz J. «Poussées inflammatoires d’acné » sous isotrétinoïne révélant une hidradénite suppurée: 4 cas. Ann Dermatol Venereol. 2019;146:4–8.
pubmed: 30224078
doi: 10.1016/j.annder.2018.07.020
Gallagher CG, Kirthi SK, Cotter CC, Revuz JR, Tobin AMT. Could isotretinoin flare hidradenitis suppurativa? A case series. Clin Exp Dermatol. 2019;44:777–80.
pubmed: 30719727
doi: 10.1111/ced.13944
Caposiena Caro RD, Bianchi L. Can retinoids flare hidradenitis suppurativa? A further case series. Clin Exp Dermatol. 2019;44:e153–4.
pubmed: 30816560
doi: 10.1111/ced.13956
Jørgensen A-HR, Thomsen SF, Ring HC. Isotretinoin and hidradenitis suppurativa. Clin Exp Dermatol. 2019;44:e155–6.
pubmed: 30802991
doi: 10.1111/ced.13953
Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218:134–5.
pubmed: 19060466
doi: 10.1159/000182261
De Vita V, Melnik BC. The magnitude of mTORC1 signalling may predict the response to isotretinoin treatment in patients with hidradenitis suppurativa. Dermatology. 2017;233:399–400.
pubmed: 29258098
doi: 10.1159/000484408
Marasca C, Balato A, Annunziata MC, Cacciapuoti S, Fabbrocini G. Insulin resistance, mTOR and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019. https://doi.org/10.1111/jdv.15271 .
doi: 10.1111/jdv.15271
pubmed: 31660646
Balato A, Caiazzo G, Annunziata MC, Marasca C, Scala E, Cacciapuoti S, et al. Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019. https://doi.org/10.1111/jdv.15160 .
doi: 10.1111/jdv.15160
pubmed: 31062452
Bouwman K, Aarts P, Dudink K, Hao J, Alizadeh BZ, Prens LM, et al. Drug survival of oral retinoids in hidradenitis suppurativa: a real-life cohort study. Am J Clin Dermatol. 2022;23:905–14.
pubmed: 36070059
pmcid: 9449939
doi: 10.1007/s40257-022-00725-9
Libow LFFDA. Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifolliculitis capitis abscedens et suffodiens: treatment with isotretinoin. Cutis. 1999;64(2):87–90.
pubmed: 10467498
Huang CM, Kirchhof MG. A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology. 2017;233:120–5.
pubmed: 28641306
doi: 10.1159/000477207
Boer J, van Gemert MJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73–6.
pubmed: 9922015
doi: 10.1016/S0190-9622(99)70530-X
Patel N, McKenzie SA, Harview CL, Truong AK, Shi VY, Chen L, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatol Treat. 2021;32:473–5.
doi: 10.1080/09546634.2019.1670779
McPhie ML, Bridgman AC, Kirchhof MG. Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients. J Cutan Med Surg. 2019;23:270–6.
pubmed: 30658534
doi: 10.1177/1203475418823529
Coskun BN, Yagiz B, Pehlivan Y, Dalkilic E. Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. Rheumatol Int. 2019;39:2159–65.
pubmed: 31455984
doi: 10.1007/s00296-019-04434-1
Schaffer LC, Schaffer CB, Hunter S, Miller A. Psychiatric reactions to isotretinoin in patients with bipolar disorder. J Affect Disord. 2010;122:306–8.
pubmed: 19783054
doi: 10.1016/j.jad.2009.09.005
Tzur Bitan D, Berzin D, Cohen A. Hidradenitis suppurativa and bipolar disorders: a population-based study. Dermatology. 2020;236:298–304.
pubmed: 31910425
doi: 10.1159/000504535
Zito PM, Mazzoni T. Acitretin. In: StatPearls. Treasure Island: StatPearls Publishing; 2023.
Ganzetti G, Campanati A, Santarelli A, Pozzi V, Molinelli E, Minnetti I, et al. Periodontal disease: an oral manifestation of psoriasis or an occasional finding? Drug Dev Res. 2014. https://doi.org/10.1002/ddr.21194 .
doi: 10.1002/ddr.21194
pubmed: 25381976
Pilkington T, Brogden RN. Acitretin. Drugs. 1992;43:597–627.
pubmed: 28421560
doi: 10.2165/00003495-199243040-00010
Ortiz NEG, Nijhawan RI, Weinberg JM. Acitretin. Dermatol Ther. 2013;26:390–9.
pubmed: 24099069
doi: 10.1111/dth.12086
Guenther LC, Kunynetz R, Lynde CW, Sibbald RG, Toole J, Vender R, et al. Acitretin use in dermatology. J Cutan Med Surg. 2017;21:2S-12S.
pubmed: 28952335
doi: 10.1177/1203475417733414
Tu J, Yin Z, Guo J, He F, Long F, Yin Z. Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ. Int Immunopharmacol. 2020;79: 106045.
pubmed: 31863918
doi: 10.1016/j.intimp.2019.106045
Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5.
pubmed: 20874789
doi: 10.1111/j.1365-2133.2010.10071.x
Matusiak Ł, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170–4.
pubmed: 24506875
doi: 10.1111/bjd.12884
Sánchez-Díaz M, Díaz-Calvillo P, Rodríguez-Pozo JÁ, Arias-Santiago S, Molina-Leyva A. Effectiveness and safety of acitretin for the treatment of hidradenitis suppurativa, predictors of clinical response: a cohort study. Dermatology. 2023;239:52–9.
pubmed: 35998603
doi: 10.1159/000526019
Tan MG, Shear NH, Walsh S, Alhusayen R. Acitretin. J Cutan Med Surg. 2017;21:48–53.
pubmed: 27432818
doi: 10.1177/1203475416659858
Molinelli E, Sapigni C, Simonetti O, D’Agostino GM, Brisigotti V, Rizzetto G, et al. Acitretin plus macrolides and acitretin monotherapy in the management of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023. https://doi.org/10.1111/jdv.18706 .
doi: 10.1111/jdv.18706
pubmed: 36682048
Puri N, Talwar A. A study on the management of hidradenitis suppurativa with retinoids and surgical excision. Indian J Dermatol. 2011;56:650.
pubmed: 22345763
pmcid: 3276889
doi: 10.4103/0019-5154.91821
Chen A-W, Chen Z, Bai X-M, Luo X-Y, Wang H. Successful treatment of early-onset hidradenitis suppurativa with acitretin in an infant with a novel mutation in PSENEN gene. Indian J Dermatol Venereol Leprol. 2022;88:445.
pubmed: 35146980
doi: 10.25259/IJDVL_471_19
D’Ambra I, Caccavale S, Ronchi A, Franco R, Argenziano G. A case of hidradenitis suppurativa and Darier disease in a patient treated with acitretin: how to kill two birds with one stone. Italian J Dermatol Venereol. 2022. https://doi.org/10.23736/S2784-8671.20.06568-2 .
doi: 10.23736/S2784-8671.20.06568-2
Sachdev SS, Jamil A, Gunabalasingam P, Safdar NA. The effects of acitretin on insulin resistance, glucose metabolism, and lipid levels in patients with psoriasis. Indian J Dermatol. 2022;67(4):349–54.
pubmed: 36578705
pmcid: 9792046
Diepgen T, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92:251–5.
pubmed: 22281779
doi: 10.2340/00015555-1256
Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17:437–43.
pubmed: 18321241
doi: 10.1517/13543784.17.3.437
Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150(2):155–62 (Epub 2014 Jun 13).
pubmed: 24927170
Bubna A. Alitretinoin in dermatology—an update. Indian J Dermatol. 2015;60:520.
pubmed: 26538721
pmcid: 4601442
doi: 10.4103/0019-5154.164426
Prasad S, Bygum A. Successful treatment with alitretinoin of dissecting cellulitis of the scalp in keratitis-ichthyosis-deafness syndrome. Acta Derm Venereol. 2013;93:473–4.
pubmed: 23150172
doi: 10.2340/00015555-1499
Motamedi M, Chehade A, Sanghera R, Grewal P. A clinician’s guide to topical retinoids. J Cutan Med Surg. 2022;26:71–8.
pubmed: 34292058
doi: 10.1177/12034754211035091
Thielitz A, Abdel-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne—an evidence-based overview. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2008;6:1023–31.
pubmed: 18479477
doi: 10.1111/j.1610-0387.2008.06741.x
Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015;173:1132–41.
pubmed: 26215715
doi: 10.1111/bjd.14053
Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24:167–97.
pubmed: 16677965
doi: 10.1016/j.det.2006.01.001
Scheinfeld N. Hidradenitis suppurativa in prepubescent and pubescent children. Clin Dermatol. 2015;33:316–9.
pubmed: 25889132
doi: 10.1016/j.clindermatol.2014.12.007
Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Perifolliculitis capitis abscedens et suffodiens successfully controlled with topical isotretinoin. Eur J Dermatol. 2003;13(2):192–5.
pubmed: 12695138
Das K, Daveluy S, Kroumpouzos G, Agarwal K, Podder I, Farnbach K, et al. Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. J Clin Med. 2022;11:670.
pubmed: 35160122
pmcid: 8836901
doi: 10.3390/jcm11030670
Marasca C, Fabbrocini G, Abategiovanni L, Camela E, Nocerino M, Di Guida A, et al. Adalimumab in the management of isotretinoin-induced acne fulminans: report of a case. Skin Appendage Disord. 2021;7:115–9.
pubmed: 33796557
pmcid: 7991494
doi: 10.1159/000512032
Clinicaltrials.gov and Pubmed.ncbi.nlm.nih.gov.